Table 1.

Enhancement of the In vivo Antiangiogenic Effect of IL-12 in BALB/c Mice

TreatmentConcentration (IL-12 Equivalent), μg% Corneal Surface Area Occupied by Vessels (Mean)% Decrease versus Control
Control43.4 ± 2.1
mrIL-120.2536.7 ± 6.215.5
mrIL-12vp0.2526.7 ± 4.738.5*
Control33.8 ± 11.0
mrIL-120.529.3 ± 6.213.3
mrIL-12vp0.511.2 ± 3.066.9*,†
Control36.7 ± 018.2
Sham33.5 ± 10.08.7
mrIL-12116.5 ± 1.155.0*
mrIL-12vp16.6 ± 1.082.0*,†
  • *P < 0.05 compared with control-treated mice.

  • P < 0.05 compared with mrIL-12-treated mice.

  • Mice treated with representative cell culture supernatant fractions from nontransfected CHO cells.